Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Pharmacokinetic, Dose-response and Safety Study of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain

NCT04713189 is registered in ClinicalTrials.gov with Lee's Pharmaceutical Limited as lead sponsor.

NCT NCT04713189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04713189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Pharmacokinetic, Dose-response and Safety Study of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
Lead sponsor
Lee's Pharmaceutical Limited
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 15, 2021
Completion date
December 21, 2021
Enrollment
96 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breakthrough cancer pain